Comparison of the major clinical outcomes for the use of endeavor® and resolute integrity® zotarolimus-eluting stents during a three-year follow-up
- Authors
- Kim, Y.H.; Her, A.-Y.; Rha, S.-W.; Choi, B.G.; Choi, S.Y.; Byun, J.K.; Park, Y.; Kang, D.O.; Jang, W.Y.; Kim, W.; Choi, C.U.; Park, C.G.; Seo, H.S.
- Issue Date
- 2020
- Publisher
- Ubiquity Press
- Keywords
- Clinical outcomes; Drug-eluting stent; Zotarolimus
- Citation
- Global Heart, v.15, no.1
- Indexed
- SCIE
SCOPUS
- Journal Title
- Global Heart
- Volume
- 15
- Number
- 1
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/60796
- DOI
- 10.5334/GH.374
- ISSN
- 2211-8160
- Abstract
- Background: Endeavor®-zotarolimus-eluting stent (E-ZES) was the first ZES to be developed, and Resolute integrity®-ZES (I-ZES) has been developed more recently. Comparative studies on long-term usage of these two ZESs have been rare. Objectives: The aim of this study was to compare the efficacy and safety of E-ZES and I-ZES during a long-term follow-up of patients who underwent percutaneous coronary intervention (PCI). Methods: A total of 767 patients who underwent PCI with E-ZES or I-ZES were eligible for this study. The primary endpoint was the occurrence of major adverse cardiac events (MACEs), defined as the composite of all-cause death, non-fatal myocardial infarction (MI), and any repeat revascularization. The secondary endpoint was stent thrombosis (ST). Results: After propensity score-matched (PSM) analysis, two PSM groups (193 pairs, n = 386, C-statistic = 0.824) were generated. During the 3-year follow-up period, the cumulative incidence of MACEs (hazard ratio [HR], 0.837; 95% confidence interval [CI], 0.464-1.508; p = 0.553) and ST (HR, 0.398; 95% CI, 0.077-2.052; p = 0.271) was similar for the E-ZES and I-ZES groups. Additionally, the cumulative incidences of all-cause death, cardiac death, non-fatal MI, and any repeat revascularization were not significantly different between the two groups. Conclusions: Although I-ZES utilizes a more advanced stent platform, stent design, and polymer system than E-ZES, both the ZESs showed comparable efficacy and safety during the 3-year follow-up period in this single-center, all-comers registry. However, further large-scaled, randomized, well-controlled trials with long-term follow-up are needed to verify these results. Copyright: © 2020 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.